Impact of clinical pharmacist intervention in the treatment of pemphigus with rituximab at a tertiary care hospital
DOI:
https://doi.org/10.18203/2320-6012.ijrms20242607Keywords:
Pemphigus, Rituximab, PDAI, DLQI, Clinical pharmacistAbstract
Background: Pemphigus is an autoimmune bullous disease that causes lesions and blisters over skin and mucous membrane. Treatment involves long-term administration of systemic corticosteroids and/or other immunosuppressive agents. Rituximab is a type of monoclonal antibody target specific cells in the body. PDAI score is used to measure the extent of pemphigus. DLQI questionnaire is used to interpret the quality of life. Aim was to evaluate the impact of clinical pharmacist intervention in the treatment of pemphigus with rituximab.
Methods: A prospective interventional study was carried out in dermatology department. 40 patients diagnosed with pemphigus were included in the study. The demographic data, lab parameters, PDAI score and DLQI questionnaire were collected before and after infusion and pharmacist intervention. The data were statistically analyzed using paired t-test.
Results: Females represented the majority of the study population. The mean±SD of age was found to be 44.57±12.90. During rituximab administration majority of the patients experienced no adverse events. Notably, hypertension emerged as the most commonly reported adverse effect. Before the intervention, the mean±SD for PDAI was found to be 29±19.78 and DLQI was found to be 9.55±4.32. After the intervention, the mean±SD for PDAI was found to be 24.25±18.13 and DLQI was found to be 7.925±3.99. The values are analyzed using paired t-test and have significance with p value <0.0001.
Conclusions: Clinical pharmacist intervention regarding treatment, disease and life style modification having a significant improvement in patients with pemphigus.
References
Kasperkiewicz M, Ellebrecht CT, Takahashi H, Yamagami J, Zillikens D, Payne AS et. al. Pemphigus. Nat Rev Dis Primers. 2017;3(1):1-8.
Kridin K, Schmidt E. Epidemiology of pemphigus. JID Innov. 2021;1(1):100004.
Kanwar AJ, De D. Pemphigus in India. IJDVL. 2011;77:439.
Heelan K, Hassan S, Bannon G, Knowles S, Walsh S, Shear NH, et al. Cost and resource use of pemphigus and pemphigoid disorders pre-and post-rituximab. J Cutan Med Surg. 2015;19(3):274-82.
Frampton JE. Rituximab: a review in pemphigus vulgaris. Am J Clin Dermatol. 2020;21(1):149-56.
Snast I, Spitzer L, Hodak E, Levi A, Mimouni D, Leshem YA. Treatment of pemphigus vulgaris and foliaceus with adjuvant rituximab compared to immunosuppression alone: real-life experience. Dermatology. 2021;237(2):179-84.
Naseer SY, Gill L, Shah J, Sinha AA. Gender-based variability in disease presentation in pemphigus vulgaris. J Drug Dermatol. 2014;13(10):1225-30.
Mitev A, Rencz F, Tamási B, Hajdu K, Péntek M, Gulácsi L, et al. Subjective well-being in patients with pemphigus: a path analysis. Eur J Health Econ. 2019;20:101-7.
Buonavoglia A, Leone P, Dammacco R, Di Lernia G, Petruzzi M, Bonamonte D, et al. Pemphigus and mucous membrane pemphigoid: An update from diagnosis to therapy. Autoimmun Rev. 2019;18(4):349-58.
Tallab T, Joharji H, Bahamdan K, Karkashan E, Mourad M, Ibrahim K. The incidence of pemphigus in the southern region of Saudi Arabia. Int J Dermatol. 2001;40(9):570-2.
Elmas ÖF, Demirbaş A, Türsen Ü, Atasoy M, Lotti T. Pemphigus and COVID‐19: critical overview of management with a focus on treatment choice. Dermatol Ther. 2020;33(6):e14265.
Hébert V, Vermeulin T, Tanguy L, Tedbirt B, Mignard C, Bénichou J, et al. Comparison of real costs in the French healthcare system in newly diagnosed patients with pemphigus for first‐line treatment with rituximab vs. standard corticosteroid regimen: data from a national multicentre trial. Br J Dermatol. 2020;183(1):121-7.
Fortuna G, Calabria E, Ruoppo E, Adamo D, Aria M, Amato M, et al. The use of rituximab as an adjuvant in the treatment of oral pemphigus vulgaris. J Oral Pathol Med. 2020;49(1):91-5.
Lamberts A, Euverman HI, Terra JB, Jonkman MF, Horváth B. Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases. Front Immunol. 2018;9:248.
Aryanian Z, Balighi K, Nassimi M, Hatami P, Shahandashti MI, Goodarzi A, et al. Rituximab treatment and improvement of health-related quality of life in patients with pemphigus. Cutis. 2023;111(1):53-6.
